2.31

1.28% -0.03

Lexicon Pharmaceuticals Inc (LXRX)

Overview News Price History Option Chain Financials Why LXRX Down? Discussions Forecast Stock Split

Lexicon Pharmaceuticals Inc stock is traded at $2.31, with a volume of 2.77M. It is down -1.28% in the last 24 hours and down -3.75% over the past month. Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Previous Close:

$2.34

Open:

$2.32

24h Volume:

2.77M

Relative Volume:

0.85

Market Cap:

$1.03B

Revenue:

$69.64M

Net Income/Loss:

$-26.09M

P/E Ratio:

-32.31

EPS:

-0.0715

Net Cash Flow:

$-38.80M

1W Performance:

+0.87%

1M Performance:

-3.75%

6M Performance:

+99.14%

1Y Performance:

+115.89%

1-Day Range:

$2.245

$2.35

1-Week Range:

$2.16

$2.415

52-Week Range:

$1.02

$2.68

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Name

Lexicon Pharmaceuticals Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

(281) 863-3000

Address

2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS

Employee

Twitter

@LexPharma

Next Earnings Date

2026-08-05

Latest SEC Filings

LXRX's Discussions on Twitter

Compare LXRX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LXRX Lexicon Pharmaceuticals Inc	2.31	990.56M	69.64M	-26.09M	-38.80M	-0.0715
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jun-17-24	Initiated	H.C. Wainwright	Buy
Apr-30-24	Initiated	Leerink Partners	Outperform
Mar-07-23	Initiated	Jefferies	Hold
Aug-12-22	Initiated	Piper Sandler	Overweight
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy
Jul-29-19	Downgrade	Stifel	Buy → Hold
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Mar-01-17	Reiterated	H.C. Wainwright	Buy
Mar-01-17	Reiterated	Wedbush	Outperform
Oct-07-16	Initiated	H.C. Wainwright	Buy
Aug-05-16	Reiterated	Wedbush	Outperform
Aug-02-16	Initiated	Citigroup	Buy
Mar-02-16	Reiterated	Wedbush	Outperform
Nov-09-15	Reiterated	Wedbush	Outperform
Sep-28-15	Upgrade	Gabelli & Co	Sell → Hold
Sep-18-15	Downgrade	Gabelli & Co	Hold → Sell
Aug-10-15	Downgrade	JP Morgan	Overweight → Neutral

View All

Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News

Jul 27, 2026

Lexicon (LXRX) Completes Patient Randomization in Key Phase 3 Tr - GuruFocus

Jul 27, 2026

Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment - marketscreener.com

Jul 27, 2026

Lexicon's HCM study spans 20 countries; results anticipated Q1 2027 - Stock Titan

Jul 27, 2026

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM) - Yahoo Finance Australia

Jul 27, 2026